1021 related articles for article (PubMed ID: 18192896)
1. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
[TBL] [Abstract][Full Text] [Related]
2. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
3. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
[TBL] [Abstract][Full Text] [Related]
4. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI
Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
[TBL] [Abstract][Full Text] [Related]
5. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.
Kulkantrakorn K; Tassaneeyakul W; Tiamkao S; Jantararoungtong T; Prabmechai N; Vannaprasaht S; Chumworathayi P; Chen P; Sritipsukho P
Pain Pract; 2012 Mar; 12(3):202-8. PubMed ID: 21676164
[TBL] [Abstract][Full Text] [Related]
6. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
[TBL] [Abstract][Full Text] [Related]
7. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China.
Wu XT; Hu FY; An DM; Yan B; Jiang X; Kwan P; Stefan H; Zhou D
Epilepsy Behav; 2010 Nov; 19(3):405-8. PubMed ID: 20833111
[TBL] [Abstract][Full Text] [Related]
8. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of toxic epidermal necrolysis.
Lee MT; Hung SI; Wei CY; Chen YT
Expert Opin Pharmacother; 2010 Sep; 11(13):2153-62. PubMed ID: 20536296
[TBL] [Abstract][Full Text] [Related]
10. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
Chung WH; Hung SI
J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
[TBL] [Abstract][Full Text] [Related]
12. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F
N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195
[TBL] [Abstract][Full Text] [Related]
13. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.
Ko TM; Chung WH; Wei CY; Shih HY; Chen JK; Lin CH; Chen YT; Hung SI
J Allergy Clin Immunol; 2011 Dec; 128(6):1266-1276.e11. PubMed ID: 21924464
[TBL] [Abstract][Full Text] [Related]
14. Genetic predisposition of life-threatening antiepileptic-induced skin reactions.
Chung WH; Hung SI; Chen YT
Expert Opin Drug Saf; 2010 Jan; 9(1):15-21. PubMed ID: 20001755
[TBL] [Abstract][Full Text] [Related]
15. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole.
Wanat KA; Anadkat MJ; Klekotka PA
J Am Acad Dermatol; 2009 Apr; 60(4):589-94. PubMed ID: 19217690
[TBL] [Abstract][Full Text] [Related]
16. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study.
Gau SS; Chao PF; Lin YJ; Chang CJ; Gau CS
J Clin Psychopharmacol; 2008 Oct; 28(5):509-17. PubMed ID: 18794645
[TBL] [Abstract][Full Text] [Related]
17. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
Kim SH; Kim M; Lee KW; Kim SH; Kang HR; Park HW; Jee YK
Pharmacogenomics; 2010 Jun; 11(6):879-84. PubMed ID: 20504258
[TBL] [Abstract][Full Text] [Related]
18. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Harr T; French LE
Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
[TBL] [Abstract][Full Text] [Related]
19. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.
Hung SI; Chung WH; Liu ZS; Chen CH; Hsih MS; Hui RC; Chu CY; Chen YT
Pharmacogenomics; 2010 Mar; 11(3):349-56. PubMed ID: 20235791
[TBL] [Abstract][Full Text] [Related]
20. Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know?
Tartarone A; Lerose R
Ther Drug Monit; 2010 Dec; 32(6):669-72. PubMed ID: 20844465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]